Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation (RE-DUAL PCI trial) - Shown is the cumulative incidence of the primary end point of major or clinically relevant nonmajor bleeding in the group that received dual therapy with dabigatran at a dose of 110 mg versus the group that received triple therapy with warfarin (Panel A) #EBM #Cardiology #IM #REDUAL #Dabigatran #DualTherapy #TripleTherapy #PCI #AtrialFibrillation #NEJM
